In 2023, Yan M. et al. demonstrated that Siglec-9, an immune-checkpoint molecule on macrophages, could be targeted to enhance the therapeutic efficacy of anti-PD-1/PD-L1 for GBM treatment [35]. This evidence concerns the gene PDCD1 and glioblastoma.